{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:04:22Z","timestamp":1761059062253},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1673,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1177\/0091270010365558","type":"journal-article","created":{"date-parts":[[2010,4,27]],"date-time":"2010-04-27T01:52:50Z","timestamp":1272333170000},"page":"271-278","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetic Interactions Between Darunavir\/Ritonavir and Opioid Maintenance Therapy Using Methadone or Buprenorphine\/Naloxone"],"prefix":"10.1002","volume":"51","author":[{"given":"Vanitha","family":"Sekar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Tomaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"De Pauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Vangeneugden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Hoetelmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"10.1177\/0091270010365558-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10550490490265271","article-title":"Hepatitis C and HIV infections: implications for clinical care in injection drug users","volume":"13","author":"Sullivan","year":"2004","journal-title":"Am J Addict"},{"key":"10.1177\/0091270010365558-BIB2|cit2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0376-8716(00)00121-6","article-title":"Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment","volume":"61","author":"Eap","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"10.1177\/0091270010365558-BIB3|cit3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00003495-200969050-00006","article-title":"Buprenorphine\/naloxone: a review of its use in the treatment of opioid dependence","volume":"69","author":"Orman","year":"2009","journal-title":"Drugs"},{"key":"10.1177\/0091270010365558-BIB4|cit4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00007691-200202000-00005","article-title":"HIV drug interactions: the good, the bad, and the other","volume":"24","author":"Rainey","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.1177\/0091270010365558-BIB5|cit5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/376907","article-title":"The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients","volume":"37","author":"McCance-Katz","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1177\/0091270010365558-BIB6|cit6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-2125.2001.00342.x","article-title":"The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz","volume":"51","author":"Clarke","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1177\/0091270010365558-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"10.1177\/0091270010365558-BIB8|cit8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"TITAN study group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1177\/0091270010365558-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","article-title":"Once-daily darunavir\/ritonavir vs lopinavir\/ritonavir in treatment-na\u00efve, HIV-1-infected patients: 96-week analysis of ARTEMIS","volume":"23","author":"Mills","year":"2009","journal-title":"AIDS"},{"key":"10.1177\/0091270010365558-BIB10|cit10","unstructured":"Tibotec 2009 PREZISTA\u2122 (darunavir) full prescribing information http:www.prezista.comprezistadocumentsuspackageinsert.pdf"},{"key":"10.1177\/0091270010365558-BIB11|cit11","unstructured":"Tibotec 2009 PREZISTA\u2122 (darunavir). Summary of product characteristics http:www.emea.europa.euhumandocsPDFsEPARprezistaemea-combined-h707en.pdf"},{"key":"10.1177\/0091270010365558-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350801300101","article-title":"Darunavir: pharmacokinetics and drug interactions","volume":"13","author":"Back","year":"2008","journal-title":"Antiviral Ther"},{"key":"10.1177\/0091270010365558-BIB13|cit13","unstructured":"Symoron\u00a9 product information 2001 http:www.epgonline.orgviewdrug.cfmdrugIdDR000650languagelg0012drugNameSymoron"},{"key":"10.1177\/0091270010365558-BIB14|cit14","unstructured":"Suboxone\u00a9 product information revised 2007 http:www.rxlist.comsuboxone-drug.htm"},{"key":"10.1177\/0091270010365558-BIB15|cit15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/JCP.0b013e3180592ad2","article-title":"Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients","volume":"27","author":"Uehlinger","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1177\/0091270010365558-BIB16|cit16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1526-4637.2006.00289.x","article-title":"Actual and potential drug interactions associated with methadone","volume":"9","author":"Weschules","year":"2008","journal-title":"Pain Med"},{"key":"10.1177\/0091270010365558-BIB17|cit17","unstructured":"Bouche MP Michielsen L Piot M Timmerman P Swift and simultaneous determination of darunavir and ritonavir in human plasma using LC-MS\/MS August 2006"},{"key":"10.1177\/0091270010365558-BIB18|cit18","unstructured":"AIDS Clinical Trials Group 2004 Division of AIDS table for grading the severity of adult and pediatric events http:www.ucdmc.ucdavis.educlinicaltrialsdocumentsDAIDSAEGradingTableFinalDec2004.pdf"},{"key":"10.1177\/0091270010365558-BIB19|cit19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0306-4603(90)90036-W","article-title":"The development of a short opiate withdrawal scale (SOWS): brief report","volume":"15","author":"Gossop","year":"1990","journal-title":"Addict Behav"},{"key":"10.1177\/0091270010365558-BIB20|cit20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0306-4603(01)00201-5","article-title":"Initial validation of two opiate craving questionnaires: the Obsessive Compulsive Drug Use Scale and the Desires for Drug Questionnaire","volume":"27","author":"Franken","year":"2002","journal-title":"Addict Behav"},{"key":"10.1177\/0091270010365558-BIB21|cit21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350801300415","article-title":"Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women","volume":"13","author":"Sekar","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1177\/0091270010365558-BIB22|cit22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003495-200969040-00007","article-title":"Darunavir, a review of its use in the management of HIV infection in adults","volume":"69","author":"McKeage","year":"2009","journal-title":"Drugs"},{"key":"10.1177\/0091270010365558-BIB23|cit23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.psy.50.2.169","article-title":"Pharmacokinetic drug interactions of synthetic opiate analgesics","volume":"50","author":"Armstrong","year":"2009","journal-title":"Psychosomatics"},{"key":"10.1177\/0091270010365558-BIB24|cit24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2008.104","article-title":"Mechanisms of ritonavir changes in methadone pharmacokinetics and pharmacodynamics, I: evidence against CYP3A mediation of methadone clearance","volume":"84","author":"Kharasch","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1177\/0091270010365558-BIB25|cit25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2008.12.009","article-title":"Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity","volume":"101","author":"Kharasch","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1177\/0091270010365558-BIB26|cit26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1592\/phco.28.7.863","article-title":"Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects","volume":"28","author":"Cao","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1177\/0091270010365558-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1592\/phco.24.13.1110.38091","article-title":"Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects","volume":"24","author":"Hendrix","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1177\/0091270010365558-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/01.aids.0000183628.20041.f2","article-title":"Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction","volume":"19","author":"Friedland","year":"2005","journal-title":"AIDS"},{"key":"10.1177\/0091270010365558-BIB29|cit29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.qai.0000219769.89679.ec","article-title":"Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice","volume":"41","author":"Bruce","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"suppl 4","key":"10.1177\/0091270010365558-BIB30|cit30","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1086\/508186","article-title":"Pharmacokinetic interactions between buprenorphine and antiretroviral medications","volume":"43","author":"Bruce","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"suppl 4","key":"10.1177\/0091270010365558-BIB31|cit31","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1086\/508188","article-title":"Interactions between buprenorphine and antiretrovirals, II: the protease inhibitors nelfinavir, lopinavir\/ritonavir, and ritonavir","volume":"43","author":"McCance-Katz","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1177\/0091270010365558-BIB32|cit32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.drugalcdep.2007.06.007","article-title":"Interaction between buprenorphine and atazanavir or atazanavir\/ritonavir","volume":"91","author":"McCance-Katz","year":"2007","journal-title":"Drug Alcohol Depend"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270010365558","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1177\/0091270010365558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T02:45:21Z","timestamp":1711421121000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1177\/0091270010365558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"URL":"https:\/\/doi.org\/10.1177\/0091270010365558","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}